ABLYNX ANNOUNCES 2009 FULL YEAR RESULTS
(Thomson Reuters ONE) -
GHENT, Belgium, 25( )February 2010 - Ablynx [Euronext Brussels: ABLX] announced
today its consolidated results for 2009, which have been prepared in accordance
with IFRS as adopted by the European Union.
2009 Highlights
* ?92.3 million in cash, cash equivalents and available-for-sale financial
assets and other short term investments at year end
* ?21.3 million net cash burn for the year
* 77% increase in revenues to ?29.7 million (2008: ?16.8 million)
* Initiated a Phase II study in September for its vWF targeting
anti-thrombotic, ALX-0081, in a head-to-head comparison with ReoPro(®) as
adjunctive treatment to standard anti-thrombotic therapy in "high risk"
patients undergoing a percutaneous coronary intervention (PCI) procedure.
Showed proof-of-concept by biomarker for ALX-0081 in December with data from
the open label extension of its Phase Ib study
* Reported positive Phase I results for its anti-vWF Nanobody product,
ALX-0681, which is being developed in patients with thrombotic
thrombocytopenic purpura (TTP)
* Received Orphan Drug Designation from both the FDA and EMEA for its vWF
Nanobody programme for the treatment of TTP
* Pfizer successfully completed Phase I trials and initiated Phase II trials
for its anti-TNFa Nanobody product in rheumatoid arthritis (RA) patients in
September, which triggered a $4 million milestone payment to Ablynx
* Initiated a Phase I study in December for its RANKL targeting Nanobody,
ALX-0141, in healthy postmenopausal women. The drug is being developed
initially for the treatment of osteoporosis
* Announced a new pre-clinical development candidate, ALX-0061, a Nanobody
product targeting IL-6R, for the treatment of autoimmune and inflammatory
diseases
* Successfully generated functional Nanobodies against GPCRs
* Awarded a total of ?1.1 million in grants to further develop new routes of
administration for Nanobodies
* Announced important developments in the administration of Nanobody products
via pulmonary and needle-free routes together with more data on its novel
proprietary half-life extension technology called NExpedite(®)
* Received ?9 million in milestone payments from Boehringer Ingelheim, as part
of its strategic alliance
For more information, please contact:
College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, Dr John McIntyre
t: +44 (0)20 7866 7857
e: ablynx(at)collegehill.com
Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan(at)ablynx.com
Wim Ottevaere
Chief Financial Officer
t: +32 (0)9 262 00 11
e: wim.ottevaere(at)ablynx.com
[HUG#1388791]
Complete version of the press release: http://hugin.info/137912/R/1388791/346990.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.02.2010 - 12:11 Uhr
Sprache: Deutsch
News-ID 1010738
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Ghent
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 253 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX ANNOUNCES 2009 FULL YEAR RESULTS
"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
